Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 4Lymphoma, Large B-Cell, Diffuse 2Leukemia 2Sezary Syndrome 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Mastocytosis, Systemic 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Prolymphocytic 1Leukemia, Myeloid, Acute 1Leukemia, Hairy Cell 1Leukemia, Biphenotypic, Acute 1Intraocular Lymphoma 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1Blast Crisis 1

Interventions

Cyclophosphamide 87fludarabine 77fludarabine phosphate 45Tacrolimus 45Whole-Body Irradiation 42Mycophenolic Acid 42Busulfan 35Melphalan 32Antilymphocyte Serum 24Methotrexate 23thymoglobulin 22Standard of Care 22Rituximab 22venetoclax 20Thiotepa 20Sirolimus 20Azacitidine 20Stem Cell Transplantation 18Granulocyte Colony-Stimulating Factor 18Practice Guidelines as Topic 17Cytarabine 16Bortezomib 16Nivolumab 15Filgrastim 15Specimen Handling 14Dexamethasone 14Blood Specimen Collection 14Cyclosporine 13Surveys and Questionnaires 12Mesna 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × obatoclax × Other hematologic neoplasm × Clear all
NCT00438178 2014-05-12

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1 Completed
44 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡